Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. In a recent update, Novo Nordisk is conducting a study titled ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

Researchers at the University of Utah say new weight loss drugs pose new questions about what happens to muscle mass and ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which ...

NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

A study has found that prescribing semaglutide in everyday clinical settings led to modest but meaningful improvements in cardiovascular risk alongside a rise in non-drug healthcare costs. The study, ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Semaglutide, a GLP-1 receptor agonist, has already shown benefits for weight loss and cardiovascular health. This new study adds to growing evidence that the drug’s effects may extend to ...